Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Magrolimab : A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Breast<br/>CancersCancer LocationBreast
Cancers

Systemic therapy,Treatment | BreastBreast

Trial Overview Read MoreRead more

This trial is evaluating the addition of a targeted cancer drug (Magrolimab) to chemotherapy (using Nab-Paclitaxel or Paclitaxel) for the treatment of people with triple negative breast cancer that has spread to other parts of the body.
 

This trial is treating patients with triple negative breast cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer

Commercial Sponsor

Gilead Sciences

Summary

Eligible participants will include a safety run-in cohort to establish a recommended phase two dose (RP2D) of Magrolimab. Following the safety run-in cohort, eligible participants will be randomised into one of two experimental treatment arms. Participants in one arm will receive the RP2D of Magrolimab in combination with Nab-Paclitaxel (100mg/m^2) or Paclitaxel (90mg/m^2) on Days 1, 8 and 15 of each 28-day treatment cycle. Participants in the other arm won't receive treatment with Magrolimab.

Recruiting Hospitals Read MoreRead more

Box Hill Hospital, Breast Oncology
Box Hill
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Barwon Health, University Hospital Geelong
Geelong
Oncology Team
OncologyTrials@barwonhealth.org.au

Maroondah Hospital, Maroondah Breast Clinic
Ringwood East
Ms Karen Lim
karen.lim@monash.edu
03 9094 9564

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next